HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ELAN

Elanco Animal Health Incorporated (NYSE)

Healthcare — Drug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Strong Buy 1.4 / 5 14 analysts
$24.09
$-0.52 (-2.11%)
Target: $29.86 (23.9%)
Sign in to add ELAN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$12.03B
P/E Ratio (TTM)-
Forward P/E20.26
EPS (TTM)$-0.50
Dividend Yield-
Profit Margin-4.95%
Revenue Growth14.90%
ROE-3.77%
Debt/Equity66.15
Recommendation Strong Buy 1.4
Analyst Target$29.86
Analysts14
Indexes NYSE

Technical Indicators

RSI (14)59.5
Beta1.70
SMA 20-
SMA 40-
52-Week High$27.72
52-Week Low$13.39
50-Day Avg$23.08
200-Day Avg$22.85
Avg Volume$5.80M
Volume$3.40M

Performance Analysis

BULLISH

ELAN shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 75% of its 52-week range.
+ RSI at 59.5 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 14.9% year-over-year.
- Operating at a loss with -4.9% margin.
+ Wall Street consensus is "Strong Buy" from 14 analysts.
+ Average analyst target of $29.86 implies 23.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:07 UTC

Back to Screener Export Report